Predisposing variables include male gender, smoking, high RF and ACPA titers, severe arthritis, and HLA predisposition (HLADRB1).9 This delayed onset highlights the importance of long-term monitoring for patients taking MTX, even if they don’t show obvious clinical symptoms. The gene discussed is PRTN3; the disease is Arthritis.